«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

23卷

期数:

2017年01期

页码:

59-62

栏目:

临床医学

出版日期:

2017-01-16

文章信息/Info

Title:

Clinical observation of early application of different doses of trofiban in patients with acute ST-segment elevation myocardial infarction

文章编号:

1006-8147（2017）01-0059-04

作者:

刘 杰; 宋书凯

(潍坊医学院内科学教研室, 潍坊 261053 )

Author(s):

LIU Jie;  SONG Shu-kai

(Department of Internal Medicine, Weifang Medical University, Weifang 261053, China)

关键词:

急性ST段抬高型心肌梗死; 替罗非班; 冠状动脉介入治疗; 心肌再灌注

Keywords:

acute ST-segment elevation myocardial infarction; tirofiban;  percutaneous coronary intervention; myocardial reperfusion

分类号:

R542.2+2

DOI:

-

文献标志码:

A

摘要:

目的： 探讨早期应用不同剂量替罗非班对急性ST段抬高型心肌梗死（STEMI）患者的临床疗效和安全性。方法： 选取急诊行冠状动脉支架植入术（PCI）的103例STEMI患者，按照随机数字表法，根据给药时间分为早期给药组（67例）和晚期给药组（36例），早期给药组根据药物剂量又分为低剂量组（33例）和常规剂量组（34例）。观察3组患者术前、术后梗死相关血管TIMI血流分级，术后90 min ST段抬高回落百分比，心肌损伤标志物变化，术后7 d内出血事件及30 d内心血管不良事件发生率。结果: （1）3组术后TIMI 3级血流患者比例均显著高于术前（均P <0.05），早期给药组TIMI 3级血流比例显著高于晚期给药组（P <0.05）。（2）早期给药组90 min ST段回落百分比明显高于晚期给药组（P <0.05），而早期两组组间比较无差异（P >0.05）。（3）与晚期给药组相比，早期给药组可显著降低术后CK-MB水平（P <0.05），但3组术后cTnI水平无明显差异（P >0.05）。（4）3组主要心血管事件（MACE）发生率无明显差异（P >0.05），低剂量组出血发生率低于常规剂量组（P <0.05），而血小板减少发生率无明显差异（P >0.05）。结论:早期应用替罗非班可改善急性STEMI患者PCI术后心肌血流的再灌注，且未增加临床不良事件的发生风险。低剂量与常规剂量相比，疗效相当，且出血发生率更低，安全性更高。

?

Abstract:

Objective: To evaluate the clinical effect and safety of early application of different doses of tirofiban in patients with acute ST-segment elevation myocardial infarction（STEMI）. Methods： One hundred and three cases of patients with STEMI receiving emergency coronary stenting were randomized into early administration of tirofiban group（n=67）and later administration group（n=36）according to the time of drug administration；The early administration group was divided into low dose group (33 cases) and conventional dose group (34 cases) .The TIMI flow classification, the percentage of ST segment depression at 90 min, myocardial markers, 7-day bleeding events and 30-day adverse cardiovascular events were observed and compared among the three groups before and after operation. Results：（1）The TIMI 3 flow grade after operation in the three groups were significantly higher than those before operation (P<0.05), and the proportion of the TIMI 3 grade flow in the early administration group was significant higher than that in the later administration group (P<0.05).（2）The percentage of ST segment depression at 90 min in the early administration group was significantly higher than that in the later treatment group (P<0.05), and the former two groups had no significant difference (P>0.05).（3）Compared with the later administration group, the levels of CK-MB in the early treatment group decreased significantly (P>0.05)，but the cTnI levels had no significant differences in the three groups (P>0.05).（4）The incidence of major cardiovascular events (MACE) in the three groups presented no significant differences (P>0.05). The hemorrhage incidence in low dose group was significantly lower than that in conventional dose group (P<0.05), but thrombocytopenia occurred rate had no significant difference (P>0.05). Conclusion：Early application of tirofiban could significantly improve myocardial reperfusion and clinical outcomes in patients with STEMI undergoing PCI. Compared with the conventional dose, the bleeding incidence of low dose is lower, and the safety is higher.

参考文献/References:

[1]Nienaber C A. Guidelines for percutaneous coronary interventions[J]. Eur Heart J, 2006, 27(1757): 1757[2]Hahn J Y, Song Y B, Kim E K, et al. Ischemic postconditioning during primary percutaneous coronary intervention the effects of postconditioning on myocardial reperfusion in patients with ST-Segment elevation myocardial infarction (POST) randomized trial[J]. Circulation, 2013, 128(17): 1889
[3]谢英，刘锼，周玉杰，等．高危急性冠状动脉综合征介入治疗早期或即刻应用替罗非班对主要不良心血管事件的影响[J]．中华心血管病杂志，2009，37（01）：39
[4]Huber A H, Kampf J P, Kwan T, et al. Usefulness of serum unbound free fatty acid levels to predict death early in patients with ST-segment elevation myocardial infarction (from the Thrombolysis In Myocardial Infarction [TIMI] II trial)[J]. Am J Cardiol, 2014, 113(2): 279
[5]Kuliczkowski W, Gasior M, Pres D, et al. Aspirin’resistance’:impact on no-reflow,platelet and inflammatory biomarkers in diabetics after ST-segment elevation myocardial infarction[J]. Cardiology, 2015, 131(1): 41
[6]Kurtul A, Murat S N, Yarlioglues M, et al. Increased neutrophil-to-lymphocyte ratio predicts persistent coronary no-flow after wire insertion in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Clinics (Sao Paulo), 2015, 70(1): 34
[7]王洪涛，孟庆阳，廖序东，等．冠状动脉内注射替罗非班对急诊介入治疗中无复流的影响[J]．中华急诊医学杂志，2016，25（6）：822
[8]宋双双，刘玲玲，司良毅．早期应用替罗非班对老年急性ST段抬高型心肌梗死患者冠状动脉支架植入术后心肌血流再灌注的影响[J]．中华老年病研究电子杂志，2015，2（03）：30
[9]Yan H B, Li S Y, Song L, et al. Thrombus aspiration plus intra-infarct-related artery administration of tirofiban improves myocardial perfusion during primary angioplasty for acute myocardial infarction[J]. Chin Med J (Engl), 2010, 123(7): 877
[10]王燕庆，朱国斌，周学敏，等．替罗非班在冠心病中的应用[J]．中华临床医师杂志:电子版，2016，10（9）：1333
[11]Akpek M, Sahin O, Sarli B, et al. Acute effects of intracoronary tirofiban on No-Reflow phenomena in patients with ST-Segment elevated myocardial infarction undergoing primary percutaneous coronary intervention[J]. Angiology, 2015, 66(6): 560
[12]Michelakis E D, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension[J]. Circulation, 2003, 108(17): 2066
[13]Hermanides R S, Ottervanger J P, Ten B J, et al. Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding:effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score[J]. J Invasive Cardiol, 2012, 24(3): 84
[14]Pels K, Schroder J, Witzenbichler B, et al. Prehospital versus periprocedural abciximab in ST-elevation myocardial infarction treated by percutaneous coronary intervention[J]. Eur J Emerg Med, 2008, 15(6): 324
[15]Stone G W, Bertrand M E, Moses J W, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial[J]. JAMA, 2007, 297(6): 591

相似文献/References:

[1]崔利军,马向红,段雯婷,等.SYNTAX积分与急性心肌梗死急诊介入治疗后心血管事件的关系[J].天津医科大学学报,2015,21(03):43.
　CUI Li-jun,MA Xiang-hong,DUAN Wen-ting,et al.SYNTAX score and cardiovascular events in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention[J].Journal of Tianjin Medical University,2015,21(01):43.
[2]崔利军,马向红,段雯婷,等.SYNTAX积分与急性心肌梗死急诊介入治疗后心血管事件的关系[J].天津医科大学学报,2015,21(01):43.
　CUI Li-jun,MA Xiang-hong,DUAN Wen-ting,et al.SYNTAX score and cardiovascular events in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention[J].Journal of Tianjin Medical University,2015,21(01):43.
[3]赵晓彬,牛书林,邱久纯,等.初始血清阴离子间隙与急性ST段抬高型心肌梗死院内死亡的关系研究[J].天津医科大学学报,2023,29(02):109.
　ZHAO Xiao-bin,NIU Shu-lin,QIU Jiu-chun,et al.Relationship between initial serum anion gap and in-hospital mortality in patients with acute ST-segment elevation myocardial infarction[J].Journal of Tianjin Medical University,2023,29(01):109.
[4]刘勇,张美云,胡冠群,等.针灸联合替罗非班对急性进展性脑梗死的疗效研究[J].天津医科大学学报,2024,30(03):245.[doi:10.20135/j.issn.1006-8147.2024.03.0245]
　LIU Yong,ZHANG Mei yun,HU Guanqun,et al.Effect of acupuncture and moxibustion combined with tirofiban on patients with acute progressive cerebral infarction[J].Journal of Tianjin Medical University,2024,30(01):245.[doi:10.20135/j.issn.1006-8147.2024.03.0245]

备注/Memo

备注/Memo:

作者简介 刘杰 （1989-），女，硕士在读。研究方向：心血管内科学;通信作者：宋书凯，E-mail:songshukai.wf@163.com。

常用功能

更新日期/Last Update: 2017-01-16